AstraZeneca (NASDAQ:AZN) Shares Acquired Rep. Bruce Westerman

Representative Bruce Westerman (R-Arkansas) recently bought shares of AstraZeneca PLC NASDAQ: AZN. In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on March 3rd. The trade occurred in the Representative's "FISHER IRA" account.

• Beyond Rigetti: Top 3 Quantum Computing Stock Picks

Representative Bruce Westerman also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of LVMH Moët Hennessy - Louis Vuitton, Société Européenne OTCMKTS: LVMUY on 4/2/2025.
• Purchased $1,001 - $15,000 in shares of Sony Group NYSE: SONY on 3/24/2025.
• Purchased $1,001 - $15,000 in shares of Mitsubishi UFJ Financial Group NYSE: MUFG on 3/21/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 3/21/2025.
• Sold $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Medtronic NYSE: MDT on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 3/20/2025.

AstraZeneca Trading Up 0.7 %

AZN stock traded up $0.49 during mid-day trading on Friday, reaching $67.54. The company had a trading volume of 3,796,013 shares, compared to its average volume of 5,229,660. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The firm has a 50 day moving average of $73.00 and a 200 day moving average of $70.65. The company has a market capitalization of $209.47 billion, a PE ratio of 29.89, a price-to-earnings-growth ratio of 1.42 and a beta of 0.49.

• 3 Momentum Stocks Soaring Into 2025 and Beyond

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. On average, equities analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, March 24th. Shareholders of record on Friday, February 21st were given a dividend of $1.03 per share. This is a boost from AstraZeneca's previous semi-annual dividend of $0.49. The ex-dividend date was Friday, February 21st. This represents a yield of 2%. AstraZeneca's payout ratio is 91.15%.

Analysts Set New Price Targets

• Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Several research firms recently weighed in on AZN. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. Morgan Stanley initiated coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating for the company. Finally, BNP Paribas began coverage on AstraZeneca in a research note on Tuesday. They issued an "outperform" rating and a $75.00 target price for the company. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $86.80.

Check Out Our Latest Research Report on AstraZeneca

Hedge Funds Weigh In On AstraZeneca

Several institutional investors have recently modified their holdings of the stock. Confluence Investment Management LLC acquired a new stake in AstraZeneca in the first quarter valued at $27,000. FNY Investment Advisers LLC bought a new stake in shares of AstraZeneca in the first quarter worth $29,000. Banque Transatlantique SA bought a new stake in shares of AstraZeneca in the 4th quarter valued at $26,000. Highline Wealth Partners LLC increased its stake in shares of AstraZeneca by 447.4% in the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock valued at $31,000 after acquiring an additional 340 shares in the last quarter. Finally, Mascagni Wealth Management Inc. acquired a new position in shares of AstraZeneca during the fourth quarter worth approximately $29,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

• Five stocks we like better than AstraZeneca
• P/E Ratio Calculation: How to Assess Stocks
• 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
• Are Penny Stocks a Good Fit for Your Portfolio?
• These 3 Stocks Have Huge Last 12 Months Shareholder Yields
• How to Calculate Options Profits
• Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AstraZeneca Right Now?

Before you consider AstraZeneca, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.

While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here